

AMPHOTERICIN B – AMBISOME This drug must be guardrailed

Trade Name	Ambisome - liposomal amphotericin										
Class	Polyene antifungal										
Mechanism of Action	Binds to steroidal alcohols in the cell membrane of susceptible fungi, causing loss of membrane integrity and leakage of fungal cell contents.										
Indications Individual ID approval required for full treatment course	Systemic treatment of suspected or proven fungal infections. Active against <i>Candida species</i> , <i>Aspergillus</i> , <i>Cryptococcus</i> .										
Contraindications	History of allergy to amphotericin or any of its constituents. Use with caution in infants with renal or hepatic impairment.										
Supplied As	50 mg powder for reconstitution Contact Pharmacy Sterile Unit (extension 80839) to make up syringes of liposomal amphotericin – see stability section										
Dilution *Two dilution steps required* Preference is to have Pharmacy prepare this drug for 7 days due to the high cost of the vials	<p>Depending on the dose, dilution and size of the baby this drug can either be infused via the Alaris pump and be guardrailed or for smaller volumes (<10mL) via the T34 pump.</p> <table border="1"> <thead> <tr> <th>Vial</th> <th>Water Added</th> <th>Final Volume</th> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td>50mg</td> <td>12mL*</td> <td>12.5mL</td> <td>4mg/mL</td> </tr> </tbody> </table> <p>*50mg of ambisome powder displaces 0.5mL of water Shake vigorously for 30 secs until powder appears dispersed Then further dilute by taking 1mL (4mg) and make up to 10mL with 5% dextrose, using the 5 micron filter provided to make a final concentration of 0.4 mg/mL (400 microg/mL) See stability section below for further information on concentrations</p>			Vial	Water Added	Final Volume	Concentration	50mg	12mL*	12.5mL	4mg/mL
Vial	Water Added	Final Volume	Concentration								
50mg	12mL*	12.5mL	4mg/mL								
Dosage	Start at 1 mg/kg once a day, then, Increase in increments of 1mg/kg/day to a maximum of 5 mg/kg/day for severe infection eg: meningitis, osteoarthritis, cryptococcus or aspergillus infection										
Guardrails	Concentration: Min – 0.4 mg/mL Max – 2mg/mL Soft Alert Min: 0.5mg/kg/hr Hard Alert Max: 5mg/kg/hr Soft Alert Max: 2.5mg/kg/hr Default Setting: 1mg/kg/hr										
Interval	24 hourly										

Compatible With	Water for injection, dextrose 5%; heparin at terminal injection site. Y site compatibility with: acyclovir, cefazolin, cefuroxime, dexamethasone, dexmedetomidine, furosemide, hydrocortisone sodium succinate, milrinone, phenobarbital, potassium chloride, sulfamethoxazole-trimethoprim.
Incompatible With	0.9% sodium chloride, TPN, Lipid, and Blood products.
Administration	IV: Over at least 1 hour (infusing <1 hour have been associated with hyperkalaemia) Test dose: Acute reactions to amphotericin are usually related to the rate of infusion. Observe the baby closely during initial doses, and slow infusion if necessary. Our rates for infusion fall into manufacturer's guidelines for a test dose. Be careful of fluid volumes in small babies (refer to dilution information) Do not use in-line filter of <1 micron gauge.
Interactions	Monitor renal function when used in combination with other nephrotoxic agents, eg: aminoglycosides, vancomycin. Caution with drugs affecting serum potassium (eg corticosteroids), potentiation of potassium-related toxicity (eg digoxin), all drugs affecting bone marrow function, non-depolarising skeletal muscle relaxants (eg pancuronium).
Monitoring	Renal and hepatic function, full blood count, K ⁺ , Mg ⁺⁺
Stability	General product information says chemically stable 72 hours after reconstitution in fridge. The data current in pharmacy (2007) suggests that solutions of liposomal amphotericin in dextrose 5% at concentrations ranging between 0.4 mg/mL and 2 mg/mL are stable for up to seven days when made up in the pharmacy and stored at 2- 8 °C. Fluid and glucose tolerance will need to be assessed on an individual basis. – consult pharmacist for further assistance. Due to the change in infusion pump parameters the maximum recommended concentration for infants weighing less than 1kg is 1 mg/mL.
Storage	Protect from direct sunlight. Powder for reconstitution is stored at room temperature. Reconstituted solution kept in the fridge 2-8°C.

Adverse Reactions	<p>Acute infusion reactions (common, especially if infused too fast) - fever, shaking, dyspnoea, GI effects, headache, hypotension.</p> <p>Nephrotoxicity: increased urea and creatinine (oliguria uncommon), hypokalaemia, hypomagnesaemia, renal tubular acidosis. Effects may be prolonged (months). Caution with other nephrotoxic drugs.</p> <p>Wide range of less common side-effects: cardiovascular, haematological (raised and depleted cell counts possible), GI, CNS, skin, musculoskeletal.</p> <p>Adverse effects are less frequently reported with the liposomal preparation, but trials in neonates are lacking.</p>																						
Metabolism	<p>Liposomal amphotericin has lower renal, CSF and bone marrow tissue levels than conventional preparation (animal studies). Detailed metabolic pathways not studied in humans. Highest tissue levels in liver and spleen.</p>																						
Comments	<p>Seek specialist advice before starting amphotericin and when deciding on duration of treatment.</p> <p>Amphotericin is sometimes used in combination with other antifungals including 5-flucytosine or fluconazole.</p> <p>Ensure adequate hydration while on amphotericin.</p> <p>In-line filters may be used with amphotericin infusions provided the pore size is ≥ 1micron.</p> <p>There is potential for cost saving if doses are drawn up in Pharmacy</p>																						
References	<ol style="list-style-type: none"> 1. Neofax 13th Edition 2000, p6-9 2. Medicines for Children RCPCH 1999, p32-5 3. Fungizone Datasheet July 1997 4. Ambisome Datasheet May 2001 5. Trissel LA, Handbook on Injectable Drugs 11th Edition, 2001. Am Society of Health Systems Pharmacists (Editors) 6. www.medsafe.govt.nz 7. Notes on Injectable Drugs 7th Edition 8. New Zealand Formulary www.nzf.org.nz 																						
Updated By	<table> <tr> <td>Bevan Headley</td> <td>Sept 2002</td> </tr> <tr> <td>Kirsten Simonsen</td> <td>April 2003</td> </tr> <tr> <td>K Simonsen (stability data)</td> <td>Nov 2003</td> </tr> <tr> <td>P Schmidt, B Robertshawe</td> <td>March 2006</td> </tr> <tr> <td>B Robertshawe</td> <td>Feb 2007</td> </tr> <tr> <td>A Lynn, Robertshawe</td> <td>March 2008</td> </tr> <tr> <td>A Lynn, B Robertshawe, F Robertson</td> <td>May 2009 (new pumps)</td> </tr> <tr> <td>A Lynn, B Robertshawe</td> <td>September 2009</td> </tr> <tr> <td>A Lynn, B Robertshawe</td> <td>Nov 2012 (re-order profile, two dilutions)</td> </tr> <tr> <td>A Lynn, Tony Walls (Paed ID)</td> <td>July 2013 (PHARMAC update Ab approvals)</td> </tr> <tr> <td>A Lynn, M Wallenstein, B Robertshawe, A Evison</td> <td>May 2020</td> </tr> </table>	Bevan Headley	Sept 2002	Kirsten Simonsen	April 2003	K Simonsen (stability data)	Nov 2003	P Schmidt, B Robertshawe	March 2006	B Robertshawe	Feb 2007	A Lynn, Robertshawe	March 2008	A Lynn, B Robertshawe, F Robertson	May 2009 (new pumps)	A Lynn, B Robertshawe	September 2009	A Lynn, B Robertshawe	Nov 2012 (re-order profile, two dilutions)	A Lynn, Tony Walls (Paed ID)	July 2013 (PHARMAC update Ab approvals)	A Lynn, M Wallenstein, B Robertshawe, A Evison	May 2020
Bevan Headley	Sept 2002																						
Kirsten Simonsen	April 2003																						
K Simonsen (stability data)	Nov 2003																						
P Schmidt, B Robertshawe	March 2006																						
B Robertshawe	Feb 2007																						
A Lynn, Robertshawe	March 2008																						
A Lynn, B Robertshawe, F Robertson	May 2009 (new pumps)																						
A Lynn, B Robertshawe	September 2009																						
A Lynn, B Robertshawe	Nov 2012 (re-order profile, two dilutions)																						
A Lynn, Tony Walls (Paed ID)	July 2013 (PHARMAC update Ab approvals)																						
A Lynn, M Wallenstein, B Robertshawe, A Evison	May 2020																						